The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MM 2018 | Real world data: bortezomib-based therapy for R/R myeloma
Evangelos Terpos, MD, PhD, of the University of Athens, Athens, Greece, discusses real world data on the use of bortezomib for relapsed/refractory multiple myeloma (MM). Dr Terpos highlights the importance of these results, particularly in cases where newer drugs are not available. This interview was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.
